Enhanced Group announced that its IRB-approved clinical study on medically supervised use of FDA-approved performance-enhancing substances by elite athletes is now publicly available on ClinicalTrials.gov. The study, part of the Enhanced Medical Program, involved 36 athletes over a 12-week trial, with 91% using testosterone and other substances like human growth hormone and stimulants under individualized protocols. This research aims to ensure athlete safety while optimizing performance, with ongoing five-year health monitoring. The findings support Enhanced's approach of combining scientific oversight with personalized protocols, setting a new standard for performance medicine ahead of the inaugural Enhanced Games on May 24, 2026.
Smart Powerr Corp., a Chinese energy technology firm specializing in waste energy recycling and energy efficiency, completed a $2 million registered direct offering by selling 4.5 million shares at $0.45 each. The funds will support the company's gro...
American Fusion Inc. filed its Q1 2026 financial results reflecting the consolidation with Kepler Fusion Technologies after their reverse merger in February 2026. The company reported a net loss of $669,750 for the quarter, increased operating expens...
The US Golden Dome missile-defense system, designed to protect against ballistic, hypersonic, and cruise missiles, is under fire from Democrats and arms-control advocates. Critics warn it could cost over $1 trillion in 20 years, potentially trigger a...
Nike's stock climbed over 4% following a drop in crude oil prices and a slight decrease in long-term Treasury yields, which eased borrowing costs and improved market sentiment. The retreat in energy prices and bond yields helped revive confidence in ...
ZIM Integrated Shipping reported a 30% year-over-year sales decline to $1.40 billion in Q1 2026, missing expectations due to lower freight rates and an 8% drop in carried volume. Adjusted EBITDA fell 60% to $313 million with margins shrinking from 39...
